Atopic Dermatitis

New topline data released by Inmagene indicate positive findings from a phase 2a trial on IMG-007 for moderate-to-severe atopic dermatitis.

This analysis using worldwide data from GBD 2021 indicates that the global burden of eczema in children has gradually risen and has been projected to continue increasing.

These data expanded upon limited real-world data on retention of dupilumab past 2 years of treatment for patients with atopic dermatitis.

These interim data resulted from the JADE REAL study, with 72-week results suggesting rapid improvements in eczema severity for adults and adolescents.

In a recent study, tralokinumab demonstrates effectiveness and safety for treating moderate-to-severe atopic dermatitis in adults who are dupilumab naïve and non-naïve.

Findings suggest an association between food allergies and atopic dermatitis control and persistence.

A study showed parents of children with atopic dermatitis have an increased odds of taking medication to aid sleep.

The submission of roflumilast’s supplemental New Drug Application to the FDA by Arcutis follows the conclusion of the INTEGUMENT-PED and INTEGUMENT-OLE studies.

The approval of tapinarof cream (Vtama) for patients aged 2 years and older with eczema follows the positive findings in the ADORING trial program.

This approval announcement by Galderma follows the previous FDA approval of nemolizumab for prurigo nodularis.

This interim analysis highlights positive findings from the Measure Up 1 and 2 studies regarding upadacitinib for patients with atopic dermatitis.

These data provide insight into characteristics of those who choose to discontinue systemic therapies for eczema.

This assessment of dupilumab for pediatric and adult patients with moderate-to severe eczema treated for up to 5 years confirms the drug efficacy and safety across age groups.

These topline findings regarding MH004, or tofacitinib etocomil ointment 1.0%, demonstrated efficacy for this twice-daily pan-Jak inhibitor in adolescents and adults with eczema.

This analysis evaluated the frequency of peanut-sensitized infants and toddlers being sensitized to other types of nuts.

In this analysis in Thailand, video education’s impact on patient guardians’ knowledge was assessed with the aim of reducing eczema severity.

MJH Life Sciences, parent company of HCPLive, has acquired the RAD Annual Meeting, a premier CME-certified conference advancing dermatology knowledge and research.

These data on patients in Japan with eczema suggest there was sustained effectiveness in these patients’ clinical signs and in patient-reported outcomes.

In this analysis, patterns of global access to biologic drugs for patients with atopic dermatitis were explored among 50 countries.

New PRO data from the INTEGUMENT-1 and –2 studies were presented at the ACAAI 2024 Meeting.

More patients with atopic dermatitis on stapokibart than on placebo achieved ≥ 75% improvement in Eczema Area and Severity Index over 52 weeks.

Many with moderate-to-severe atopic dermatitis do not reach treatment targets in 12 months, underscoring a need for proactive management strategies.

In these data presented at the Fall Clinical Dermatology conference, population-based data on utilization and duration of systemic corticosteroid exposure was highlighted.

These long-term extension trial data from ADORING 3 highlight tapinarof cream’s efficacy in adults and children aged 2 years and older with atopic dermatitis.

These data from the ADapt study, presented at Fall Clinical, suggest improvements among patients with eczema given lebrikizumab-lbkz who had been previously treated with dupilumab.

These data were presented at Fall Clinical, highlighting the reductions in Eczema Area and Severity Index scores and the overall long-term safety profile of tralokinumab-ldrm.

At the Fall Clinical Dermatology conference, Chovatiya presented on chronic hand eczema and facts about its pathophysiology, diagnosis, and management.

The drug’s favorable risk-benefit profile and sustained efficacy through 76 weeks was highlighted in this analysis’s findings.